Keyword Analysis & Research: prostate cancer treatment abiraterone

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
prostate cancer treatment abiraterone	0.35	0.9	7055	48	37
prostate	1.86	0.5	6950	52	8
cancer	0.58	0.6	1536	64	6
treatment	1.73	1	9007	8	9
abiraterone	0.74	0.6	5288	91	11

Keyword	CPC	PCC	Volume	Score
prostate cancer treatment abiraterone	1.93	0.4	4111	69
abiraterone locally advanced prostate cancer	1.79	0.5	1968	49
abiraterone acetate for prostate cancer	0.83	0.5	4365	58
new prostate cancer drug abiraterone	1.51	0.5	9191	37
metastatic prostate cancer abiraterone	0.35	0.3	4810	86
radiation abiraterone prostate cancer	1.41	0.6	1462	55
abiraterone prednisone prostate cancer	0.15	0.9	1107	33
abiraterone dose in prostate cancer	0.64	0.9	8939	48
abiraterone high risk prostate cancer	1.07	0.9	4966	55
adjuvant abiraterone prostate cancer	0.6	0.1	9043	45
abiraterone dosing prostate cancer	0.72	0.6	7402	43
very high risk prostate cancer abiraterone	0.59	0.9	4365	2
abiraterone side effects prostate cancer	0.57	0.8	9820	4
abiraterone prostate cancer life expectancy	1	0.5	7162	24
stampede trial prostate cancer abiraterone	1.23	0.5	2961	14
abiraterone docetaxel prostate cancer	0.43	0.4	7865	24
is abiraterone a chemotherapy drug	1.74	0.3	509	85
abiraterona cancer de prostata	1.5	1	9332	85
abiraterone is it chemo	1.82	0.9	8819	5
is abiraterone a form of chemotherapy	1.38	0.8	2614	22

Treatment with abiraterone significantly improves survival in
harvard.edu

https://www.health.harvard.edu/blog/treatment-with-abiraterone-significantly-improves-survival-in-advanced-prostate-cancer-202201282678

WEBJan 28, 2022 · After six years of follow-up, 7% of the 986 men who received abiraterone as part of their treatment had died from prostate cancer. By contrast, 15% of the 988 men given ADT by itself had a prostate cancer death. Moreover, abiraterone significantly lengthened the time it took for metastases to appear.

DA: 50 PA: 66 MOZ Rank: 46

Abiraterone Acetate - NCI - National Cancer Institute
cancer.gov

https://www.cancer.gov/about-cancer/treatment/drugs/abirateroneacetate

WEBAbiraterone acetate is approved to be used with prednisone to treat: Prostate cancer that has metastasized (spread to other parts of the body). It is used: In patients whose cancer is castrate resistant (has not responded to treatments that lower testosterone levels). This use is approved for the Zytiga brand name of abiraterone acetate.

DA: 11 PA: 92 MOZ Rank: 12

Abiraterone for Prostate Cancer Not Previously Treated with
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa1702900

WEBJul 27, 2017 · The median duration of abiraterone treatment was 23.7 months in the ... The median time from relapse to life-prolonging therapy for castration-resistant prostate cancer (abiraterone, enzalutamide ...

DA: 31 PA: 65 MOZ Rank: 6

Abiraterone acetate and prednisolone with or without
thelancet.com

https://www.thelancet.com/article/S0140-6736(21)02437-5/fulltext

WEBDec 23, 2021 · In summary, men with high-risk non-metastatic prostate cancer who receive ADT with combination therapy have significantly better metastases-free survival and overall survival than those who receive ADT alone. 2 years of abiraterone and prednisolone added to ADT and, if indicated, radiotherapy should be considered a new …

DA: 17 PA: 55 MOZ Rank: 78

Initial Management of Noncastrate Advanced, Recurrent, or
ascopubs.org

https://ascopubs.org/doi/10.1200/JCO.20.03256

WEBJan 26, 2021 · PURPOSE Update all preceding ASCO guidelines on initial hormonal management of noncastrate advanced, recurrent, or metastatic prostate cancer. METHODS The Expert Panel based recommendations on a systematic literature review. Recommendations were approved by the Expert Panel and the ASCO Clinical Practice …

DA: 34 PA: 2 MOZ Rank: 83